Who
Katherine A. High
Director
Company insider
Files Form 4 as: Director, Incyte; Director, CRISPR Therapeutics AG; Director and Officer, Spark Therapeutics.
In numbers
- Trades disclosed
- 125
- Buys
- 1
- Sells
- 24
- Bought
- $16K
- Sold
- $12.8M
- Companies
- 3
- Companies where not an officer
- 2
- First trade
- 4 Feb 2015
- Last trade
- 8 Jun 2026
- Last filed
- 10 Jun 2026
Companies traded
Activity over time
1 Nov 2024 – 1 Oct 2026
Buys above the line, sells below, each month.
Every trade
| Traded | Company | What | Amount | |
|---|---|---|---|---|
| 8 Jun 2026filed 10 Jun 2026 | INCY IncyteLife-science tools | SEC FORM 4 Code A | —1,642 at $0.00 | filing |
| 8 Jun 2026filed 10 Jun 2026 | INCY Incyteoption or derivative · Life-science tools | SEC FORM 4 Code A | —6,111 at $0.00 | filing |
| 8 Jun 2026filed 10 Jun 2026 | INCY Incyteoption or derivative · Life-science tools | SEC FORM 4 Code A | —6,111 at $0.00 | filing |
| 8 Jun 2026filed 10 Jun 2026 | INCY IncyteLife-science tools | SEC FORM 4 Code A | —1,642 at $0.00 | filing |
| 5 Jun 2026filed 9 Jun 2026 | CRSP CRISPR Therapeutics AGoption or derivative · Genomics & Gene Editing | SEC FORM 4 Code A | —13,000 at $0.00 | filing |
| 5 Jun 2026filed 9 Jun 2026 | CRSP CRISPR Therapeutics AGoption or derivative · Genomics & Gene Editing | SEC FORM 4 Code A | —13,000 at $0.00 | filing |
| 10 Jun 2025filed 12 Jun 2025 | INCY Incyteoption or derivative · Life-science tools | SEC FORM 4 Code A | —9,216 at $0.00 | filing |
| 10 Jun 2025filed 12 Jun 2025 | INCY IncyteLife-science tools | SEC FORM 4 Code A | —2,518 at $0.00 | filing |
| 5 Jun 2025filed 6 Jun 2025 | CRSP CRISPR Therapeutics AGoption or derivative · Genomics & Gene Editing | SEC FORM 4 Code A | —13,000 at $0.00 | filing |
| 12 Jun 2024filed 14 Jun 2024 | INCY Incyteoption or derivative · Life-science tools | SEC FORM 4 Code A | —12,517 at $0.00 | filing |
| 12 Jun 2024filed 14 Jun 2024 | INCY IncyteLife-science tools | SEC FORM 4 Code A | —2,830 at $0.00 | filing |
| 30 May 2024filed 31 May 2024 | CRSP CRISPR Therapeutics AGoption or derivative · Genomics & Gene Editing | SEC FORM 4 Code A | —13,000 at $0.00 | filing |
| 14 Jun 2023filed 16 Jun 2023 | INCY Incyteoption or derivative · Life-science tools | SEC FORM 4 Code A | —11,294 at $0.00 | filing |
| 14 Jun 2023filed 16 Jun 2023 | INCY IncyteLife-science tools | SEC FORM 4 Code A | —2,505 at $0.00 | filing |
| 8 Jun 2023filed 9 Jun 2023 | CRSP CRISPR Therapeutics AGoption or derivative · Genomics & Gene Editing | SEC FORM 4 Code A | —13,000 at $0.00 | filing |
| 15 Jun 2022filed 17 Jun 2022 | INCY Incyteoption or derivative · Life-science tools | SEC FORM 4 Code A | —9,124 at $0.00 | filing |
| 15 Jun 2022filed 17 Jun 2022 | INCY IncyteLife-science tools | SEC FORM 4 Code A | —2,144 at $0.00 | filing |
| 9 Jun 2022filed 10 Jun 2022 | CRSP CRISPR Therapeutics AGoption or derivative · Genomics & Gene Editing | SEC FORM 4 Code A | —12,000 at $0.00 | filing |
| 10 Jun 2021filed 14 Jun 2021 | CRSP CRISPR Therapeutics AGoption or derivative · Genomics & Gene Editing | SEC FORM 4 Code A | —10,000 at $0.00 | filing |
| 26 May 2021filed 28 May 2021 | INCY IncyteLife-science tools | SEC FORM 4 Code A | —1,923 at $0.00 | filing |
News
No headline names them, or the companies they trade most, lately.
Sectors
Related people
Nobody else traded the same names lately.